About: Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study
Creator	Shu, Qiang Xu, Jianguo Zou, Bin Cheng, Baoli Deng, Keqin Ge, Menghua Hu, Yaoqin Huang, Lanfang Tong, Haijiang Zhang, Liuya Zheng, Guoping
Source	PMC
abstract	BACKGROUND: Recent studies have demonstrated that mesenchymal stem cells (MSCs) modulate the immune response and reduce lung injury in animal models. Currently, no clinical studies of the effects of MSCs in acute respiratory distress syndrome (ARDS) exist. The objectives of this study were first to examine the possible adverse events after systemic administration of allogeneic adipose-derived MSCs in ARDS patients and second to determine potential efficacy of MSCs on ARDS. METHODS: Twelve adult patients meeting the Berlin definition of acute respiratory distress syndrome with a PaO(2)/FiO(2) ratio of < 200 were randomized to receive allogeneic adipose-derived MSCs or placebo in a 1:1 fashion. Patients received one intravenous dose of 1 × 10(6) cells/kg of body weight or saline. Possible side effects were monitored after treatment. Acute lung injury biomarkers, including IL-6, IL-8 and surfactant protein D (SP-D), were examined to determine the effects of MSCs on lung injury and inflammation. RESULTS: There were no infusion toxicities or serious adverse events related to MSCs administration and there were no significant differences in the overall number of adverse events between the two groups. Length of hospital stay, ventilator-free days and ICU-free days at day 28 after treatment were similar. There were no changes in biomarkers examined in the placebo group. In the MSCs group, serum SP-D levels at day 5 were significantly lower than those at day 0 (p = 0.027) while the changes in IL-8 levels were not significant. The IL-6 levels at day 5 showed a trend towards lower levels as compared with day 0, but this trend was not statistically significant (p = 0.06). CONCLUSIONS: Administration of allogeneic adipose-derived MSCs appears to be safe and feasible in the treatment of ARDS. However, the clinical effect with the doses of MSCs used is weak, and further optimization of this strategy will probably be required to reach the goal of reduced alveolar epithelial injury in ARDS. TRIAL REGISTRATION: Clinical trials.gov, NCT01902082
has issue date	2014-04-04(xsd:dateTime)
bibo:doi	10.1186/1465-9921-15-39
bibo:pmid	24708472
has license	cc-by
sha1sum (hex)	6226fe74210772fa23c62465ffd6a898fa88c5a7
schema:url	https://doi.org/10.1186/1465-9921-15-39
resource representing a document's title	Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study
has PubMed Central identifier	PMC3994204
has PubMed identifier	24708472
schema:publication	Respir Res
resource representing a document's body	covid:6226fe74210772fa23c62465ffd6a898fa88c5a7#body_text
is schema:about of	named entity 'study' named entity 'EFFECTS' named entity 'POTENTIAL' named entity 'MSCS' named entity 'PATIENTS' named entity 'TO EXAMINE' named entity 'RECENT' named entity 'EXIST' named entity 'POSSIBLE' named entity 'MODULATE' named entity 'dendritic cells' named entity 'viruses' named entity 'endothelial cell' named entity 'MSCs' named entity 'MSCs' named entity 'Minneapolis' named entity 'Kidney' named entity 'follow-up' named entity 'morphology' named entity 'respiratory symptoms' named entity 'ARDS' named entity 'cell culture' named entity 'ARDS' named entity 'Institutional Animal Care and Use Committee' named entity 'total bilirubin' named entity 'kidneys' named entity 'ARDS' named entity 'xenogeneic' named entity 'pathogenesis' named entity 'saline' named entity 'CD90' named entity 'Intravenous' named entity 'quality of life' named entity 'kidneys' named entity 'BD Biosciences' named entity 'follow-up' named entity 'platelet lysate' named entity 'serum' named entity 'ARDS' named entity 'flow cytometry' named entity 'MSCs' named entity 'diabetic ketoacidosis' named entity 'ARDS' named entity 'hematological malignancy' named entity 'placebo-controlled study' named entity 'ascorbic acid 2-phosphate' named entity 'MSCs' named entity 'c-peptide' named entity 'normal saline' named entity 'MSCs' named entity 'allogeneic' named entity 'long-term' named entity 'pancreatic enzymes' named entity 'New Jersey' named entity 'ARDS' named entity 'DMEM' named entity 'adipose tissues' named entity 'MSCs' named entity 'MSCs' named entity 'MSCs' named entity 'histopathological' named entity 'life technologies' named entity 'tidal volume' named entity 'MSCs' named entity 'hemocytometer' named entity 'Mice' named entity 'pneumonia' named entity 'biomarkers' named entity 'myocardial infarction' named entity 'HCV' named entity 'Adipose-derived'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software